APA

Deau B., Nicolini F. E., Guilhot J., Huguet F., Guerci A., Legros L., Pautas C., Berthou C., Guyotat D., Cony-Makhoul P., Gardembas M., Michallet M., Hayette S., Cayuela J. M., Weiss I. R., Réa D., Castaigne S., Mahon F., Guilhot F. & Rousselot P. (20111207). The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). : Leukemia research.

Chicago

Deau Bénédicte, Nicolini Franck E, Guilhot Joelle, Huguet Françoise, Guerci Agnès, Legros Laurence, Pautas Cécile, Berthou Christian, Guyotat Denis, Cony-Makhoul Pascale, Gardembas Martine, Michallet Mauricette, Hayette Sandrine, Cayuela Jean Michel, Weiss Isabelle Radford, Réa Delphine, Castaigne Sylvie, Mahon François-Xavier, Guilhot François and Rousselot Philippe. 20111207. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). : Leukemia research.

Harvard

Deau B., Nicolini F. E., Guilhot J., Huguet F., Guerci A., Legros L., Pautas C., Berthou C., Guyotat D., Cony-Makhoul P., Gardembas M., Michallet M., Hayette S., Cayuela J. M., Weiss I. R., Réa D., Castaigne S., Mahon F., Guilhot F. and Rousselot P. (20111207). The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). : Leukemia research.

MLA

Deau Bénédicte, Nicolini Franck E, Guilhot Joelle, Huguet Françoise, Guerci Agnès, Legros Laurence, Pautas Cécile, Berthou Christian, Guyotat Denis, Cony-Makhoul Pascale, Gardembas Martine, Michallet Mauricette, Hayette Sandrine, Cayuela Jean Michel, Weiss Isabelle Radford, Réa Delphine, Castaigne Sylvie, Mahon François-Xavier, Guilhot François and Rousselot Philippe. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). : Leukemia research. 20111207.